Immunogenic composition
US-2024238398-A1 · Jul 18, 2024 · US
Therapeutic compositions and methods for treating infections
US9907822B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9907822-B2 |
| Application number | US-201414761733-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 17, 2014 |
| Priority date | Jan 18, 2013 |
| Publication date | Mar 6, 2018 |
| Grant date | Mar 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure describes, in one aspect, a composition that includes a transgenic pathogen that expresses a heterologous pathogen associated molecular pattern (PAMP). In some embodiments, the pathogen may be attenuated. In some embodiments, the pathogen can include T. cruzi . In another aspect, this disclosure describes a method of treating an infection in a subject. Generally, the method includes administering to the subject, in an amount effective to treat the infection, a pathogen genetically modified to express a pathogen-associated molecular pattern (PAMP) not natively expressed by the pathogen.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a transgenic T. cruzi that expresses a heterologous pathogen associated molecular pattern (PAMP) or a damage associated molecular patterns (DAMP). 2. The composition of claim 1 wherein the PAMP comprises an agonist of at least one Toll-Like Receptor (TLR). 3. The composition of claim 2 wherein the TLR comprises TLR 1, TLR 2, or TLR 5. 4. The composition of claim 1 wherein the PAMP comprises an agonist of at least one intracellular pattern recognition receptor (PRR). 5. The composition of claim 4 wherein the PRR comprises Neuronal Apoptosis Inhibitory Protein 5/IL-1β-converting enzyme protease-activating factor (NAIP5/Ipaf). 6. The composition of claim 1 wherein the transgenic T. cruzi is attenuated. 7. A method of treating an infection in a subject, the method comprising: administering to the subject, in an amount effective to treat the infection, a T. cruzi genetically modified to express a pathogen-associated molecular pattern (PAMP). 8. The method of claim 7 wherein the T. Cruzi is attenuated.
Assignees
Inventors
Classifications
Tumour cells; Cancer cells · CPC title
Viruses; Subviral particles; Bacteriophages · CPC title
Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00) · CPC title
- A61K35/68Primary
Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma · CPC title
- C12N1/10Primary
Protozoa; Culture media therefor · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9907822B2 cover?
- This disclosure describes, in one aspect, a composition that includes a transgenic pathogen that expresses a heterologous pathogen associated molecular pattern (PAMP). In some embodiments, the pathogen may be attenuated. In some embodiments, the pathogen can include T. cruzi . In another aspect, this disclosure describes a method of treating an infection in a subject. Generally, the method inc…
- Who is the assignee on this patent?
- Univ Georgia
- What technology area does this patent fall under?
- Primary CPC classification A61K35/68. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).